


Study aim

• Compare risks for adverse outcomes in people with diabetes between groups determined by monitoring of renal function.


Method


- Diabetes cohort taken from the QICKD trial (N=35,502)
- GP records used to determine monitoring of renal function
- Composite outcome: stroke, myocardial infarct, cardiac revascularisation, end stage renal failure, or death
- Logistic regression analysis
- Known cardiovascular and renal risk factors controlled for




Results

- 12.6% had unmonitored renal function
 - 4.4% serum creatinine not measured
 - 9.8% proteinuria not measured
- People with unmonitored renal function
 - Significantly higher incidence of adverse vascular and renal outcomes than those with normal renal function
 Odds ratios with no hypertension (1.33, 95% CI 1.07 to 1.66) and hypertension (1.42, 95% CI 1.17 to 1.72), compared to normal renal function and no hypertension
 - Lower prescription rates of ACE inhibitors and ARBs (41.4%, 95% CI 40.2 to 42.6%) than people with no evidence of CKD (54.8%, 95% CI 54.1 to 55.4%) and people with CKD (71.1%, 95% CI 70.3 to 71.9%)







Principal findings

- People with diabetes whose renal function is not monitored
 have more adverse outcomes than those with normal renal function and those with proteinuria
 - appear to receive suboptimal antihypertensive therapy



